Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.65 |
| ▸ | KDR | P35968 | 10/20 | 0.62 |
| ▸ | MET | P08581 | 4/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.55 |
| ▸ | RET | P07949 | 4/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | PDXK | O00764 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558136 | 1.00 | AXL (0.65) | AXLKDRMETAURKBAURKA | |
| SCHEMBL23982910 | 0.90 | KDR (0.54) | AXLKDRMETAURKBAURKA | |
| SCHEMBL22106609 | 0.89 | AXL (0.70) | AXLKDRMETAURKBAURKA | |
| SCHEMBL1890374 | 0.89 | AXL (0.63) | AXLKDRMETAURKBAURKA | |
| SCHEMBL29073385 | 0.88 | AXL (0.59) | AXLKDRMETAURKBAURKA | |
| SCHEMBL12663554 | 0.88 | AXL (0.60) | AXLKDRMETAURKBAURKA | |
| SCHEMBL1890626 | 0.87 | KDR (0.70) | AXLKDRMETAURKBAURKA | |
| SCHEMBL12501921 | 0.87 | AXL (0.62) | AXLKDRMETAURKBAURKA | |
| SCHEMBL22505692 | 0.86 | KDR (0.60) | AXLKDRMETAURKBAURKA | |
| SCHEMBL1132598 | 0.86 | AXL (0.62) | AXLKDRMETAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143169-B1 | PROCESSES FOR THE PREPARATION OF A KINASE INHIBITOR | EXELIXIS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12497367-B2 | Processes for the preparation of a kinase inhibitor | EXELIXIS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250368606-A1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | EXELIXIS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250051284-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4452947-A1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4426678-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118176182-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-06-11 | — | — | CN | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368606-A1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | MAP3K1, MAP3K20, MAP3K10 | AXL 1007/4885KDR 2315/4885MET 903/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | AXL 515/4885KDR 22/4885MET 152/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | AXL 1100/4885KDR 2892/4885MET 2371/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | AXL 2102/4885KDR 60/4885MET 552/4885 |
| US-12497367-B2 | Processes for the preparation of a kinase inhibitor | MET, HGF, BRAF | AXL 396/4885KDR 359/4885MET 1/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | AXL 2102/4885KDR 60/4885MET 552/4885 |
| US-20250051284-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | ABL1, PRKDC, MAP3K20 | AXL 1056/4885KDR 1084/4885MET 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.